NeuroSense Receives Positive FDA Feedback on Phase 3 Study Design for PrimeC
The Type C meeting with the FDA, combined with the recent 18-month Phase 2b PARADIGM study readout, has the Company on track to commence a Phase 3 study in mid-2025 ...